AMP Amphion Innovations Plc

RNS Number:9218I
Amphion Innovations PLC
14 September 2006

                            Amphion Innovations plc

        Partner Company WellGen Appoints Dr Kathleen Mullinix as new CEO

NEW BRUNSWICK, N.J., September 14, 2006 - Amphion Innovations plc (LSE: AMP), a
developer of companies in life sciences and technology, today announces that one
of its Partner Companies, WellGen, Inc., has appointed Dr. Kathleen P. Mullinix
as its new Chief Executive Officer. WellGen is a biotechnology company using
nutrigenomics to discover and develop food ingredients for wellness products.

Effective immediately, Dr. Mullinix succeeds Dr. David A. Evans, who passed away
suddenly on June 1, 2006.

Dr. Mullinix brings more than 30 years of industry experience to the CEO
position at WellGen. Her background encompasses significant achievements in the
biotechnology industry and considerable management experience in the government,
academic and corporate sectors.  She has been a successful entrepreneur
throughout her career and has launched multiple successful ventures.

"We are truly fortunate to have Dr. Mullinix join our company at this juncture,"
said Richard C.E. Morgan, Chief Executive Officer of Amphion Innovations plc, a
leading investor in WellGen.  "She is a proven executive with an exceptional
blend of strategy and leadership skills, and experience in building and leading
biotechnology companies that make her the right person for the job as the
company enters its next stage of growth."

WellGen holds exclusive licenses to technology that can identify health and
wellness benefits of foods and food ingredients related to the expression of
certain genes.  WellGen also has license to a wide range of food and plant-based
bioactive substances for the prevention and treatment of disease.  The company
has a growing intellectual property estate that includes issued patents and
numerous pending patent applications, all related to its mission of using its
nutrigenomics technology platform to identify proprietary dietary compounds that
affect certain genes the company has targeted. WellGen is developing its
compounds that are based on scientific evidence for multiple uses related to
enhancing and maintaining wellness.

Dr. Mullinix added: "This is a tremendous time to be joining WellGen and I am
honored to be a part of the organization. I am very excited to lead this company
as we pursue the significant market opportunities that lie ahead."

Prior to joining WellGen, Dr. Mullinix advised investors on biotechnology and
pharmaceutical business opportunities with her company Kathleen P. Mullinix &
Associates, which she founded in 2002.  Before that, Dr. Mullinix served as the
founder, chairman, CEO and president of Synaptic Pharmaceutical Corporation.
There she led the company from its inception as she developed and implemented
its strategies for scientific research, business, and intellectual property,
making it a research-driven public biotechnology company and then an emerging
pharmaceutical company.

Before founding Synaptic Pharmaceutical, Dr. Mullinix served for six years as
vice provost for Columbia University.  In this role, she brought Columbia to a
leadership position in the commercial development of university intellectual
property assets.  Additionally, she was instrumental in the development of The
Audubon Research Park, which has transformed the Columbia Presbyterian Medical
Center's Washington Heights neighborhood.

From 1972-1981, Dr. Mullinix held two positions with the National Institutes of
Health, and served the organization by assisting with strategic matters
involving the scientific direction of the NIH intramural program and
implementing a novel research program in molecular biology.

Dr. Mullinix holds a Bachelor of Arts degree in chemistry from Trinity College,
a Ph.D. in chemical biology from Columbia University and was a National
Institutes of Health Postdoctoral Fellow at Harvard University.  She currently
serves on the Board of Directors of The Jackson Laboratory, Cylex, a privately
held diagnostics company, and Intellect Neuroscience, a privately held
biotechnology company.

WellGen
Patricia Lucas-Schnarre
732-214-8834 ext. 319

Amphion Innovations plc
Josh Berkman
646 747-7158

Financial Dynamics
John Gilbert
44 207 269 7169

About WellGen

WellGen, Inc., based in New Brunswick, NJ, is a biotechnology company that is
discovering and developing products for food, therapeutics, and dietary
supplement markets. WellGen's technical platform is a method of screening the
effect of food and related substances on the expression of genes associated with
human health conditions. The company has developed proprietary substances that
help reduce risk and severity for a variety of diseases. Please visit our
website at www.wellgen.com for more information.

About Amphion Innovations plc

Amphion Innovations plc is listed on the AIM Exchange in London under the symbol
AMP. Amphion's business is the formation, financing, management and development
of life sciences and technology companies, working in partnership with
corporations, governments, universities and entrepreneurs seeking to
commercialize their intellectual property.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOALJMFTMMABBBF

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024